Literature DB >> 7685616

Involvement of basic fibroblast growth factor in suramin-induced inhibition of V79/AP4 fibroblast cell proliferation.

N Bernardini1, F Giannessi, F Bianchi, A Dolfi, M Lupetti, L Citti, R Danesi, M Del Tacca.   

Abstract

The V79/AP4 Chinese hamster fibroblasts were densely stained with the anti-basic fibroblast growth factor (bFGF) antibody demonstrating an endogenous production of the peptide. The in vitro proliferation of these cells was stimulated by exogenous bFGF and the maximum growth (259% increase in 3H-thymidine incorporation into DNA) was reached with bFGF 10 ng ml-1. Inhibition of bFGF-mediated mitogenic pathway was obtained with a 15-mer antisense oligodeoxynucleotide targeted against bFGF mRNA and with suramin, a drug which blocks the biological activity of heparin-binding growth factors. bFGF antisense oligomer reduced the synthesis of DNA by 79.5 and 89.5% at 20 and 60 microM, respectively; this effect was reversed by the addition of exogenous bFGF to the culture medium. A short-term exposure to suramin 300 micrograms ml-1 produced a modest reduction in 3H-thymidine incorporation but suppressed the mitogenic effect of bFGF on V79/AP4 cells. In cells treated with suramin 300 micrograms ml-1 the drug concentration increased linearly over 3 days, reaching 13.15 micrograms mg-1 of protein; cell proliferation was inhibited in a dose-related manner as evaluated by the colony formation assay (IC50: 344.22 micrograms ml-1) and by the number of mitoses observed in culture. Furthermore, the drug induced ultrastructural alterations, consisting of perinuclear cisternae swelling, chromatin condensation, nucleolar segregation and cytoplasmic vacuolations. These findings demonstrated that the endogenous production of bFGF plays an important role in V79/AP4 fibroblasts proliferation, and the inhibition of bFGF-mediated mitogenic signalling with bFGF antisense oligomer or suramin is an effective mean of reducing cell growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685616      PMCID: PMC1968483          DOI: 10.1038/bjc.1993.227

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor.

Authors:  J A Abraham; A Mergia; J L Whang; A Tumolo; J Friedman; K A Hjerrild; D Gospodarowicz; J C Fiddes
Journal:  Science       Date:  1986-08-01       Impact factor: 47.728

3.  Suramin antiviral therapy in the acquired immunodeficiency syndrome. Clinical, immunological, and virologic results.

Authors:  A M Levine; P S Gill; J Cohen; J G Hawkins; S C Formenti; S Aguilar; P R Meyer; M Krailo; J Parker; S Rasheed
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

Review 4.  Structural characterization and biological functions of fibroblast growth factor.

Authors:  D Gospodarowicz; N Ferrara; L Schweigerer; G Neufeld
Journal:  Endocr Rev       Date:  1987-05       Impact factor: 19.871

5.  Simultaneous production of IGF-I and EGF competing growth factors by HT-29 human colon cancer line.

Authors:  J M Culouscou; M Remacle-Bonnet; F Garrouste; J Marvaldi; G Pommier
Journal:  Int J Cancer       Date:  1987-11-15       Impact factor: 7.396

Review 6.  Suramin: with special reference to onchocerciasis.

Authors:  F Hawking
Journal:  Adv Pharmacol Chemother       Date:  1978

7.  Qualitative analysis of chromosomal evolution in a colcemid-treated Chinese hamster population.

Authors:  S Simi; C M Colella; T Mariani; A Piras; G Rainaldi
Journal:  Teratog Carcinog Mutagen       Date:  1988

8.  Antiproliferative effects of suramin on lymphoid cells.

Authors:  Z Spigelman; A Dowers; S Kennedy; D DiSorbo; M O'Brien; R Barr; R McCaffrey
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

9.  Basic fibroblast growth factor enters the nucleolus and stimulates the transcription of ribosomal genes in ABAE cells undergoing G0----G1 transition.

Authors:  G Bouche; N Gas; H Prats; V Baldin; J P Tauber; J Teissié; F Amalric
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

10.  Basic fibroblast growth factor in human rhabdomyosarcoma cells: implications for the proliferation and neovascularization of myoblast-derived tumors.

Authors:  L Schweigerer; G Neufeld; A Mergia; J A Abraham; J C Fiddes; D Gospodarowicz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

View more
  2 in total

1.  Regulation of activating protein-4-associated metastases of non-small cell lung cancer cells by miR-144.

Authors:  Feng Gao; Tao Wang; Zefeng Zhang; Rui Wang; Yang Guo; Junfeng Liu
Journal:  Tumour Biol       Date:  2015-08-08

Review 2.  Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.

Authors:  Bao T Le; Prithi Raguraman; Tamer R Kosbar; Susan Fletcher; Steve D Wilton; Rakesh N Veedu
Journal:  Mol Ther Nucleic Acids       Date:  2018-11-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.